Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Douglas A. McIntyre | Dec 11, 2014 at 6:25 AM EST

43 Million Americans Have Unpaid Medical Bills

According to a new study from the Consumer Financial Protection Bureau, 42.9 million Americans have unpaid medical bills.

Jon C. Ogg | Dec 10, 2014 at 10:35 AM EST

What a Generic Celebrex Means for Pfizer and for Actavis

While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in…

Chris Lange | Dec 10, 2014 at 10:00 AM EST

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top…

Douglas A. McIntyre | Dec 10, 2014 at 6:30 AM EST

Norway’s Oil Decline Accelerating

New oil projects are being scrapped in Norway amid falling production and low oil prices.

Chris Lange | Dec 9, 2014 at 11:35 AM EST

Bellicum Sets Pricing Terms for IPO

Bellicum Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering.

Lee Jackson | Dec 9, 2014 at 8:50 AM EST

After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired?

SunTrust Robinson Humphrey analysts say in a research note that Achaogen and Cempra could be in play as acquisition targets.

Paul Ausick | Dec 8, 2014 at 8:20 AM EST

Merck, Cubist Agree to $9.5 Billion Acquisition

Merck will acquire Cubist for $102 a share, or, about $9.5 billion, including $1.1 billion in Cubist’s net debt and…

Jon C. Ogg | Dec 4, 2014 at 12:10 PM EST

MannKind Sees More Insider Selling

MannKind saw its shares trading lower on Thursday. The culprit may simply be insiders selling more shares.

Chris Lange | Dec 4, 2014 at 10:35 AM EST

Array BioPharma: When Losing a Partnership Is Good News

Array BioPharma has announced that it had reached a definitive agreement with Novartis to regain full worldwide rights to cancer…

Chris Lange | Dec 4, 2014 at 9:40 AM EST

Credit Suisse Sees 2 Biotech Stocks That Could Double in 2015

Credit Suisse has released a biotech research report that has their top picks for upside potential in the biotech segment…

Chris Lange | Dec 2, 2014 at 9:15 AM EST

Are Avanir Shareholders Getting Enough in the Buyout?

Avanir Pharmaceuticals announced that it has entered into a definitive agreement with Otsuka Pharmaceutical for a $17.00 per share buyout.

Jon C. Ogg | Dec 1, 2014 at 2:10 PM EST

5 Critical Biotech Drug Dates and Events for December

At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks.

Paul Ausick | Nov 30, 2014 at 8:25 AM EST

Regenerative Medicine Company on Track for IPO This Week

The week after the Thanksgiving holiday stacks up to be another quiet one on the IPO front.

Chris Lange | Nov 26, 2014 at 11:07 AM EST

Mixed Readings For Biotech Short Interest

ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of…

Chris Lange | Nov 24, 2014 at 10:23 AM EST

Amgen Surprise, Discontinues Stomach Cancer Drug Study

ThinkstockAmgen Inc. (NASDAQ: AMGN) announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer. This includes…

1 … 274 275 276 277 278 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

43 Million Americans Have Unpaid Medical Bills

What a Generic Celebrex Means for Pfizer and for Actavis

Are Investors Signaling Optimism in Biotechs Through Short Interest?

Norway’s Oil Decline Accelerating

Bellicum Sets Pricing Terms for IPO

After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired?

Merck, Cubist Agree to $9.5 Billion Acquisition

MannKind Sees More Insider Selling

Array BioPharma: When Losing a Partnership Is Good News

Credit Suisse Sees 2 Biotech Stocks That Could Double in 2015

Are Avanir Shareholders Getting Enough in the Buyout?

5 Critical Biotech Drug Dates and Events for December

Regenerative Medicine Company on Track for IPO This Week

Mixed Readings For Biotech Short Interest

Amgen Surprise, Discontinues Stomach Cancer Drug Study

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

‘Your Knowledge of Money and How It Works Is Nil’: Suze Orman to 62-Year-Old Who Nearly Locked His Wife Into $605 a Month

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

Health and Healthcare Articles

All Health and Healthcare Articles

43 Million Americans Have Unpaid Medical Bills

What a Generic Celebrex Means for Pfizer and for Actavis

Are Investors Signaling Optimism in Biotechs Through Short Interest?

Norway’s Oil Decline Accelerating

Bellicum Sets Pricing Terms for IPO

After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired?

Merck, Cubist Agree to $9.5 Billion Acquisition

MannKind Sees More Insider Selling

Array BioPharma: When Losing a Partnership Is Good News

Credit Suisse Sees 2 Biotech Stocks That Could Double in 2015

Are Avanir Shareholders Getting Enough in the Buyout?

5 Critical Biotech Drug Dates and Events for December

Regenerative Medicine Company on Track for IPO This Week

Mixed Readings For Biotech Short Interest

Amgen Surprise, Discontinues Stomach Cancer Drug Study

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

‘Your Knowledge of Money and How It Works Is Nil’: Suze Orman to 62-Year-Old Who Nearly Locked His Wife Into $605 a Month

Featured Reads

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.